Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination

Award Number: R37CA246239
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2024
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination - PROJECT SUMMARY Checkpoint blockade therapy of cancer has had tremendous impact, but still only a subset of patients respond. One possible explanation is that some tumor types do not have a sufficient number of somatic mutations to produce tumor-associated-antigens (TAA) that can be targeted by the immune system, specifically CD8 T cells. Recent data from our group and others suggest an alternative explanation: there are sufficient TAA, but also suboptimal cross-presentation of these antigens by suitably activated dendritic cells. We have proposed that this central problem can be addressed using a novel in situ vaccine approach which uses 1) Flt3L to recruit DC, 2) radiotherapy to load Flt3L-mobilized DC with TAA, and 3) Toll-like Receptor agonist (TLRa) to activate TAA-loaded DC for cross-presentation. We carried out an early phase trial testing this approach and observed partial and complete systemic tumor regressions at distant (untreated) tumors, improving months after therapy, and even specific elimination of malignant B cells with sparing of healthy B cells, suggesting a systemic anti-tumor immune response. However, whether this approach actually addressed this problem of insufficient TAA cross-presentation, and whether this could potentiate subsequent checkpoint blockade therapy is unknown. In this proposal, we will investigate the mechanism of the in situ blockade therapy in a mouse model we have developed and in banked, unidentified samples from two clinical trials of in situ vaccine alone or with anti-PD1 antibody therapy. First, we will assess clinical samples from the nearly completed in situ vaccine trial to assess whether the appropriate subsets of DC were recruited and whether this results in the induction of TAA-specific CD8 T cell responses. Next, we will use several unique resources in the mouse model, including a novel GFP- collaborators, a panel of CRISPR gene-edited GFP-expressing lymphoma cell lines, and a mass cytometry (CyTOF) panel to perform deep profiling of tumor-specific T cells in each therapeutic setting. Finally, we will assess samples from our newly developed clinical trial (funded by CRI) combining the in situ vaccine with anti- PD1 antibody therapy to assess whether cross-presentation of both TAA and two surrogate antigens introduced alongside the ISV (HBsAg and CRM-197) actually occurs and correlates with clinical benefit. We are well positioned to perform the proposed studies, having generated a large set of preliminary data indicating not only therapeutic opportunity but also our ability to perform high level immune monitoring of samples from our patients treated on these novel and promising clinical studies. The proposed studies are important because they will deepen our understanding of anti-tumor T cell mechanisms and address an urgent and unmet clinical need for our patients with advanced stage lymphoma, and potentially in the future, for many cancer types.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $351,924 )
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	7	4/16/2026	NON-COMPETING CONTINUATION	$35,193
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	7	1/29/2026	NON-COMPETING CONTINUATION	$316,731
														Subtotal = $351,924

Issue Date FY: 2025 ( Subtotal = $351,924 )
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	6	6/10/2025	EXTENSION WITH OR WITHOUT FUNDS	$35,193
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	6	1/20/2025	EXTENSION WITH OR WITHOUT FUNDS	$316,731
2025	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	5	4/22/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $351,924

Issue Date FY: 2024 ( Subtotal = $368,346 )
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	5	4/17/2024	NON-COMPETING CONTINUATION	$19,388
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	5	11/13/2023	NON-COMPETING CONTINUATION	$348,958
														Subtotal = $368,346

Issue Date FY: 2023 ( Subtotal = $379,977 )
2023	2023	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	4	1/5/2023	NON-COMPETING CONTINUATION	$348,958
2023	2023	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	4	8/29/2023	NON-COMPETING CONTINUATION	$31,019
2023	2023	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	4	9/6/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $379,977

Issue Date FY: 2022 ( Subtotal = $387,731 )
2022	2022	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	3	1/6/2022	NON-COMPETING CONTINUATION	$348,957
2022	2022	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	3	6/9/2022	NON-COMPETING CONTINUATION	$38,774
														Subtotal = $387,731

Issue Date FY: 2021 ( Subtotal = $387,731 )
2021	2021	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	2	1/25/2021	NON-COMPETING CONTINUATION	$19,388
2021	2021	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	2	11/3/2020	NON-COMPETING CONTINUATION	$368,343
														Subtotal = $387,731

Issue Date FY: 2020 ( Subtotal = $387,731 )
2020	2020	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	1	12/6/2019	NEW	$387,731
2020	2020	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	1	2/20/2020	NEW	$0
2020	2020	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	1	1/23/2020	NEW	$0
														Subtotal = $387,731

Grand Total All Awards = $2,615,364

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination

Award Number: R37CA246239

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2024

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer